Bio-Rad Laboratories, Inc., a leader in life science research and clinical diagnostics, has announced the expansion of its Droplet Digital PCR (ddPCR) offerings with the introduction of four new platforms. This expansion includes the launch of the QX Continuum™ ddPCR system and the QX700™ series of platforms, acquired through the recent acquisition of digital PCR developer Stilla Technologies. The new instruments enhance Bio-Rad's existing portfolio, offering improved workflow simplicity and throughput capabilities for applications in oncology, infectious disease, and genetic research. The QX Continuum system is tailored for translational research with its flexible, all-in-one configuration, while the QX700 series is designed for diverse applications such as academic research and biopharma quality control, supporting seven-color multiplexing and processing over 700 samples per day. This strategic expansion reinforces Bio-Rad's leadership in the genomics and applied science markets.